Media headlines about Urogen Pharma (NASDAQ:URGN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Urogen Pharma earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2240292100043 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
URGN has been the subject of a number of recent research reports. Raymond James Financial, Inc. initiated coverage on Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective for the company. Jefferies Group LLC initiated coverage on Urogen Pharma in a research note on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective for the company. Oppenheimer Holdings, Inc. initiated coverage on Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $32.00 price objective for the company. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, August 2nd. Finally, Cowen and Company initiated coverage on Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $26.00.
Urogen Pharma (URGN) traded down 3.19% on Tuesday, hitting $18.20. The stock had a trading volume of 20,026 shares. Urogen Pharma has a 52-week low of $11.09 and a 52-week high of $20.02. The firm’s market cap is $41.95 million. The company has a 50-day moving average price of $17.80 and a 200 day moving average price of $17.53.
TRADEMARK VIOLATION NOTICE: This story was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/09/urogen-pharma-nasdaqurgn-getting-somewhat-positive-press-coverage-study-finds.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
